Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 5/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303291 | 0.89 | CTSL (0.40) | FEN1KDM5AKDM5BGRIN2BALOX5AP | |
| SCHEMBL10303349 | 0.83 | ALOX5AP (0.37) | FEN1GRIN2BALOX5AP | |
| SCHEMBL10303362 | 0.83 | FEN1 (0.37) | FEN1KDM5AKDM5BGRIN2BALOX5AP | |
| SCHEMBL10303338 | 0.82 | FEN1 (0.36) | FEN1GRIN2BALOX5AP | |
| SCHEMBL10302706 | 0.80 | FEN1 (0.31) | FEN1GRIN2BP2RX7 | |
| SCHEMBL10303402 | 0.79 | FEN1 (0.35) | FEN1KDM5AKDM5BGRIN2BALOX5AP | |
| SCHEMBL8190076 | 0.77 | P2RX7 (0.39) | FEN1KDM5AKDM5BP2RX7CYP3A4 | |
| SCHEMBL10303359 | 0.76 | GRIN2B (0.32) | FEN1GRIN2BALOX5APCTSLCTSS | |
| SCHEMBL12738802 | 0.76 | RAB9A (0.34) | CTSLCTSSCTSK | |
| SCHEMBL4402368 | 0.76 | CCR1 (0.33) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | FEN1 2927/4885KDM5A 1880/4885KDM5B 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.